T
Terapet
Next-generation imaging solutions for nuclear medicine, including proton therapy and precision medicine
About Terapet
Terapet SA, a Geneva-based spin-off from CERN, specializes in advanced nuclear imaging technologies aimed at enhancing the precision and safety for cancer treatment. Their flagship product, Qualγscan, is a real-time, non-invasive quality assurance device for proton therapy, currently in the commercialization phase. Additionally, they are developing Nuclyscan, a next-generation total-body PET scanner designed for theranostic applications, with plans for deployment in 2026.
Source: Dealroom company dataAt a glance
- Founded
- 2019
- Headquarters
- Satigny, Switzerland
- Sector
- Health Tech & Medtech
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Nina Capital
EFI
FONGIT
Innosuisse
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Terapet on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Terapet on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.